logo-loader
viewScancell Holdings PLC

Scancell to raise up to £8mln to develop its three main drug candidates

Cliff Holloway, chief executive at Scancell Holdings Plc (LONSCLP), tells Proactive Investors they're raising up to £8mln through a placing and open offer – cash that will be used develop their three main drug candidates.

A placing and subscription at 12 pence a share will account for £6mln of the total.

The company also wants to include existing investors, so is planning a £2mln open offer of stock once the placing has been concluded.

Quick facts: Scancell Holdings PLC

Price: 5 GBX

LSE:SCLP
Market: LSE
Market Cap: £23.27 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: Scancell receives US approval for its SCIB1 skin cancer...

Headlines from the Proactive UK newsroom. Scancell (LON:SCLP) has received IND approval from the US FDA for its SCIB1 skin cancer treatment. the company will now start a US Phase 2 trial in combination with leading drug Keytruda to see if it reduces toxicity compared to other...

on 3/2/20

2 min read